Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CodeBreaK 101 master protocol for sotorasib in advanced KRAS G12C-mutated solid tumors
NL-OMON60594Phase 1Active, not recruiting
- Sponsor
- Amgen
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of sotorasib in Nonhematologic neoplasms, sponsored by Amgen. Primary endpoint: Primary endpoint(s). Started Dec 2022; status: active, not recruiting.
02
Drugs
sotorasib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON60594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60594.